Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent. A Randomized Controlled Trial in Patients Hospitalized With Heart Failure

Journal of the American College of Cardiology

Volumn 51, Issue 23, 2008, Pages 2276-2285

  Gheorghiade, Mihai ^a   Blair, John E A ^a   Filippatos, Gerasimos S ^b   Macarie, Cezar ^c   Ruzyllo, Witold ^d   Korewicki, Jerzy ^d   Bubenek Turconi, Serban I ^e   Ceracchi, Maurizio ^f   Bianchetti, Maria ^f   Carminati, Paolo ^f   Kremastinos, Dimitrios ^b   Valentini, Giovanni ^f   Sabbah, Hani N ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c National Institute of Cardiovascular Disorders   (Romania)

^d INSTITUTE OF CARDIOLOGY   (Poland)

^e CC Iliescu Heart Diseases Institute   (Romania)

^f Sigma Tau SpA   (Italy)

^g HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INOTROPIC AGENT; ISTAROXIME; NEUROHORMONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RATE; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY ARTERY CATHETER; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 44449084777     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.03.015     Document Type: Article

References (19)

1. Gheorghiade M., Zannad F., Sopko G., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
2. Gheorghiade M., Filippatos G., De Luca L., and Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 119 (2006) S3-S10
3. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
4. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
5. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 12 (2006) e1-e122
6. Shin D.D., Brandimarte F., De Luca L., et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 99 (2007) 4A-23A
7. De Luca L., Mebazaa A., Filippatos G., et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail 10 (2008) 201-213
8. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
9. Micheletti R., Mattera G.G., Rocchetti M., et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303 (2002) 592-600
10. Rocchetti M., Besana A., Mostacciuolo G., et al. Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther 313 (2005) 207-215
11. Adamson P.B., Vanoli E., Mattera G.G., et al. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol 42 (2003) 169-173
12. Sabbah H.N., Imai M., Cowart D., Amato A., Carminati P., and Gheorghiade M. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol 99 (2007) 41A-46A
13. Ghali J.K., Smith W.B., Torre-Amione G., et al. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 99 (2007) 47A-56A
14. Cleland J.G., Freemantle N., Coletta A.P., and Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110
15. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297 (2007) 1883-1891
16. Gheorghiade M., De Luca L., Fonarow G.C., Filippatos G., Metra M., and Francis G.S. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 96 (2005) 11G-17G
17. Schulz R., Rose J., Martin C., Brodde O.E., and Heusch G. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 88 (1993) 684-695
18. Gheorghiade M., Gattis Stough W., Adams Jr. K.F., Jaffe A.S., Hasselblad V., and O'Connor C.M. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol 96 (2005) 18G-25G
19. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 (2003) 997-1003